English
This article is from Indian Journal of Endocrinology and Metabolism , volume 16 . Abstract Background:: The clustering of cardiovascular risk factors is termed the metabolic syndrome (MS), which strongly predicts the risk of diabetes and cardiovascular disease (CVD). Adipokines may contribute to the development of obesity and insulin resistance and may be a causal link between MS, diabetes and CVD. Hence, we studied the adipokines – adiponectin and plasminogen activator inhibitor-1 (PAI-1) – in subjects with MS. Materials and Methods:: We studied 50 subjects with MS diagnosed by International Diabetes Federation (IDF) criteria and 24 healthy age- and sex-matched controls. Clinical evaluation included anthropometry, body fat analysis by bioimpedance, highly sensitive C-reactive protein, insulin, adiponectin, and PAI-1 measurement. Results:: Subjects with MS had lower adiponectin (4.01 ± 2.24 vs. 8.7 ± 1.77 μg/ml; P < 0.0001) and higher PAI-1 (53.85 ± 16.45 vs. 17.35 ± 4.45 ng/ml; P < 0.0001) levels than controls. Both were related with the number of metabolic abnormalities. Adiponectin was negatively and PAI-1 was positively associated with body mass index, waist hip ratio (WHR), bo
Sign in with your free account to read, download EPUBs or listen.
Ebook · Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome. · Garg, M. K., Dutta, M. K., Mahalle, Namita · Internet Archive